Q3 2026 IQVIA Earnings Conference Call - IQVIA HOLDINGS INC

Financial Performance:

• Third-quarter revenue reached $4.428 billion, growing 8% year-over-year (YoY) reported and 8.6% at constant currency; organic growth accelerated to approximately 6%, more than double the prior year's rate.
• Adjusted EBITDA was $1.032 billion, representing an 8.7% YoY growth with margins expanding 20 basis points to reach record levels; underlying operational margin improvement was 80 basis points, fully offsetting a ~70 basis point headwind from pass-through revenue mix.
• Adjusted diluted EPS came in at $3.34, up 11.3% YoY, driven entirely by operational performance and exceeding the high end of guidance.
• Year-to-date revenue stood at $12.947 billion with organic growth over 5%; GAAP net income was $880 million ($5.24 EPS), while adjusted net income was $1.576 billion ($9.38 EPS).
• Free cash flow for the quarter was $667 million, representing 120% of adjusted net income, with $2.249 billion in cash and a net leverage ratio of 3.45x.
• R&D Solutions net new bookings totaled $3.2 billion (up 15% YoY) with a 1.2 book-to-bill ratio; contracted backlog is $32.6 billion with $9.4 billion expected in the next 12 months (up 10% YoY).
• A $2.1 billion adjustment was made to the backlog for inactive trials (>18 months inactivity), which has no impact on historical results or future bookings if trials resume.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance raised to $17.35–17.50 billion (6.4–7.3% growth), reflecting >200 bps of acquisition contribution and 20 bps FX tailwind.
• Full-year 2026 adjusted EBITDA guidance raised to $4.025–4.055 billion, targeting flat margins of ~23.2% on an absolute dollar basis.
• Full-year 2026 adjusted diluted EPS guidance raised to $12.90–$13.00 (8.2–9.1% growth).
• Run-rate assumptions for Q4 2026 include net interest expense of ~$210 million, D&A of ~$160 million, and a share count of ~169 million; Q4 comparisons are noted as historically difficult.
• 2027 detailed guidance will be provided at the February 2027 earnings release, with a framework to be shared at the Investor Day on December 1st.
• Long-term outlook remains positive with biotech (EVP) funding up 85% YoY ($90 billion YTD) and clinical trial starts growing in the high single digits; new drug approvals are up 40% YoY, signaling strong commercial demand.

Business Segments and Product Lines:

• R&D Solutions (Clinical): Revenue grew 8.7% reported (7% organic), nearly tripling last year's organic rate; full-service bookings were notably strong, defying earlier "insourcing" concerns.
• Commercial Solutions: Revenue grew 6.9% reported (4% organic), doubling last year's organic rate; record pipeline levels and shortened decision timelines were reported.
• AI Integration: AI-driven "agentic" solutions are a key differentiator; Acuvia has deployed 415 agents to date, delivering value by optimizing study design, site selection, and patient engagement.
• Client Wins: Recent major wins include AI-enabled protocol optimization for a Phase III oncology program and an integrated AI platform for a top-five pharma client to generate real-time market insights.
• Sub-segments: Commercial growth was broad across Information, Analytics, Consulting, and Patient Engagement; Clinical growth was supported by a strong shift back to full-service outsourcing among large pharma.

Market and Competitive Landscape:

• The industry is emerging from a 2–3 year re-procurement and funding contraction cycle; the largest pharmaceutical companies have largely renewed strategic partnerships with IQVIA, expanding scope.
• Biotech funding ($90 billion YTD) has nearly doubled pre-pandemic annual levels, driving significant growth opportunities in the EVP sector where spending growth is projected in the upper single digits.
• IQVIA is capturing market share from smaller, mid-tier competitors who lost ground during the downturn, while large pharma has focused its spend on integrated partners with AI capabilities.
• Win rates improved by 2–3 basis points in the quarter, driven by the combination of scale, data, and AI-enabled workflow integration.

Risks and Challenges:

• Pass-through revenue mix continues to exert downward pressure on reported gross margins (approx. 70 bps headwind), requiring focus on underlying service margins.
• Foreign exchange volatility remains a factor, with an estimated 70 bps headwind projected for Q4 if current rates persist.
• The R&D business is long-cycle; while bookings are strong, revenue recognition from new bookings will take time to materialize.
• Regulatory and pricing uncertainty (e.g., IRA, MFN, tariffs) previously caused extended decision timelines, though these appear to be stabilizing.
• Macroeconomic headwinds related to currency fluctuations and potential shifts in global funding environments remain monitoring points.

Management Commentary and Tone:

• Management expressed high confidence, describing the quarter as "outstanding" with performance exceeding the high end of guidance across all key metrics.
• CEO Ari Busby emphasized that AI is a fundamental shift in doing business rather than just a technology add-on, relying on unique proprietary data, context, and interpretation to build agentic workflows.
• CFO Mike Feffer highlighted the "underlying strength" of the business, noting that 80 bps of operational improvement significantly outweighed mix and currency headwinds.
• Tone was assertive regarding the return to full-service outsourcing and the long-term growth trajectory driven by biotech funding recovery.

Analyst Questions and Answers:

• AI Differentiation: Management clarified that IQVIA's advantage lies in the combination of proprietary data, life sciences context, and the ability to build specific agentic workflows, which generic AI tools cannot replicate alone.
• Margin Trajectory: When asked about gross margin, management confirmed that without pass-throughs, underlying margins would have expanded 80 bps; future growth is driven by cost containment and AI-driven productivity.
• Booking Strength: Analysts inquired about Q3 booking seasonality; management confirmed the strength was broad-based, not unusual, and driven by sustained demand for full-service contracts.
• Backlog Scrub: The $2.1 billion backlog adjustment was explained as removing trials inactive for >18 months with no near-term resumption risk; these would be added back as bookings if work resumes.
• Interest Expense: Management advised that the $210 million Q4 interest run-rate is a valid baseline for 2027 modeling, assuming no major refinancing changes.
• Commercial Backlog: It was clarified that the commercial segment operates on shorter cycles with less reliance on backlog metrics compared to R&D; focus is on record pipeline levels and new drug launch activity.

Other Key Points:

• The company implemented a new segment reporting structure effective January 1, 2026, with prior periods recast accordingly.
• The "TechIQ" annual event was held in Boston with over 400 attendees, featuring partnerships with NVIDIA, Microsoft, AWS, Snowflake, and Viza.
• IQVIA is expanding into earlier phases of drug development (Phase I, Discovery) via acquisitions and hiring to better serve the biotech client base.
• The "pendulum" has swung back toward full-service outsourcing, with large pharma demonstrating a continued preference for integrated partners over in-sourcing.